Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization
- PMID: 11816797
- DOI: 10.1385/JMN:17:2:259
Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization
Abstract
Research over the past ten years on Alzheimer's disease has pursued many opportunities. Notable amongst the various approaches are efforts related to the "amyloid hypothesis." This hypothesis posits that the beta amyloid peptide causes the extensive neuropathology and clinical decline associated with the disease. Extensive research in this area has shown that the beta amyloid peptide is produced by proteases termed "secretases" and it has been shown that blockade of secretase functions reduce the amount of beta amyloid peptide produced. An additional approach to reduce beta amyloid, through an increase in clearance mechanisms, is to immunize with the peptide itself and induce an antibody response. The specifically elicited antibodies then bind to and stimulate clearance of the peptide from the brain. These findings have stimulated several approaches to develop novel therapeutic strategies to treat Alzheimer's disease that either are about or have entered the clinic.
Similar articles
-
Secretases as targets for the treatment of Alzheimer's disease: the prospects.Lancet Neurol. 2002 Nov;1(7):409-16. doi: 10.1016/s1474-4422(02)00188-6. Lancet Neurol. 2002. PMID: 12849363 Review.
-
BACE1: the beta-secretase enzyme in Alzheimer's disease.J Mol Neurosci. 2004;23(1-2):105-14. doi: 10.1385/JMN:23:1-2:105. J Mol Neurosci. 2004. PMID: 15126696 Review.
-
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.Hum Mol Genet. 2001 Jun 1;10(12):1317-24. doi: 10.1093/hmg/10.12.1317. Hum Mol Genet. 2001. PMID: 11406613
-
The secretases of Alzheimer's disease.Curr Top Dev Biol. 2003;54:233-61. doi: 10.1016/s0070-2153(03)54011-x. Curr Top Dev Biol. 2003. PMID: 12696752 Review. No abstract available.
-
Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.J Neurosci Res. 2006 May 15;83(7):1252-61. doi: 10.1002/jnr.20818. J Neurosci Res. 2006. PMID: 16511867
Cited by
-
Oral administration of a fusion protein between the cholera toxin B subunit and the 42-amino acid isoform of amyloid-β peptide produced in silkworm pupae protects against Alzheimer's disease in mice.PLoS One. 2014 Dec 3;9(12):e113585. doi: 10.1371/journal.pone.0113585. eCollection 2014. PLoS One. 2014. PMID: 25469702 Free PMC article.
-
Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.Neural Plast. 2012;2012:272374. doi: 10.1155/2012/272374. Epub 2012 Jun 26. Neural Plast. 2012. PMID: 22792491 Free PMC article. Review.
-
Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals.Biomolecules. 2013 Oct 2;3(4):741-77. doi: 10.3390/biom3040741. Biomolecules. 2013. PMID: 24970190 Free PMC article.
-
beta-Amyloid degradation and Alzheimer's disease.J Biomed Biotechnol. 2006;2006(3):58406. doi: 10.1155/JBB/2006/58406. J Biomed Biotechnol. 2006. PMID: 17047308 Free PMC article.
-
Can novel therapeutics halt the amyloid cascade?Alzheimers Res Ther. 2010 Apr 9;2(2):5. doi: 10.1186/alzrt28. Alzheimers Res Ther. 2010. PMID: 20388189 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous